Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vivos Therapeutics, Inc.VVOS · Entity 8396 | Director · Chief Medical Officer · 10% owner | August 05, 2021 | August 11, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vivos Therapeutics, Inc.
Report date August 05, 2021 · Filed August 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.72 · Expires 2026-08-05 | Direct | 46,667 |
Reported balance
After 2021-08-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-08-05 · Grant · Acquired 30,000 · Balance 46,667 F2: 30,000 stock options granted on August 5, 2021. One-half vested immediately and one-eighth vests quarterly every three months through August 5, 2022. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,219,705 |
Reported balance
Holding disclosure · report date 2021-08-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 3,219,705 F1: Shares held by Himmat LP, of which reporting person is a member and manager. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by Himmat LP, of which reporting person is a member and manager.
F2: 30,000 stock options granted on August 5, 2021. One-half vested immediately and one-eighth vests quarterly every three months through August 5, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2021 Filed Aug 11, 2021 01:44 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $2.72 Strike: $2.72 | $81,600.00 |
DisclosureSEC source: 0001493152-21-019251 · ownership.xml · derivative · entry 2 Singh Gurdev Dave · CIK 0001835538 · Director · Chief Medical Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,667 Underlying: Common Stock · 46,667 shares Expires 2026-08-05 F2 · derivative.exercise_date: 30,000 stock options granted on August 5, 2021. One-half vested immediately and one-eighth vests quarterly every three months through August 5, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.